(Alliance News) - Sanofi SA and Brentford, west London-based GlaxoSmithKline PLC have kicked off the next phase of a trial of their Covid-19 vaccine candidate, the French pharmaceutical firm said on Thursday.
The duo have recruited 400 participants for Phase 1/2 of the study of their adjuvanted recombinant protein-based vaccine candidate.
This part of the study probes the tolerability and effectiveness of the vaccine candidate and the companies expect to report first results in early December. They also aim to begin phase 3 of the trial before the end of the year, should results from the current stage be promising.
In August, GSK said it was in advanced discussions with the European Union to supply up to 300 million doses of the vaccine.
Glaxo said the doses would be manufactured in European countries including France, Belgium, Germany and Italy. It noted that the discussions mark a key milestone in protecting and serving the European population against Covid-19.
The UK, meanwhile, has secured access to six different vaccine candidates, including the Sanofi and GSK venture.
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Glaxosmithkline (GSK)
